| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial
|
Velloza, Jennifer
|
|
|
12 |
2 |
p. e105-e117
|
article
|
| 2 |
Artificial intelligence powers HIV testing services in Kenya
|
Pebody, Roger
|
|
|
12 |
2 |
p. e92-e93
|
article
|
| 3 |
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study
|
Hendrickson, Cheryl
|
|
|
12 |
2 |
p. e130-e142
|
article
|
| 4 |
Creativity until you drop dead
|
Burki, Talha
|
|
|
12 |
2 |
p. e94
|
article
|
| 5 |
Dolutegravir plus lamivudine treatment without HIV drug-resistance tests
|
Llibre, Josep M
|
|
|
12 |
2 |
p. e82-e83
|
article
|
| 6 |
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial
|
Cordova, Ezequiel
|
|
|
12 |
2 |
p. e95-e104
|
article
|
| 7 |
Event-driven PrEP beyond cisgender men who have sex with men
|
Irie, Whitney C
|
|
|
12 |
2 |
p. e143-e153
|
article
|
| 8 |
Interpreting unit costs of PrEP services by effective use
|
Terris-Prestholt, Fern
|
|
|
12 |
2 |
p. e86-e87
|
article
|
| 9 |
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE
|
Grinspoon, Steven K
|
|
|
12 |
2 |
p. e118-e129
|
article
|
| 10 |
Preventing HIV in young women in Africa
|
Gengiah, Tanuja N
|
|
|
12 |
2 |
p. e83-e84
|
article
|
| 11 |
Risk estimation in HIV reveals our usual blind spots
|
Durand, Madeleine
|
|
|
12 |
2 |
p. e85-e86
|
article
|
| 12 |
Steps toward quick and equitable roll-out of lenacapavir
|
The Lancet HIV,
|
|
|
12 |
2 |
p. e81
|
article
|
| 13 |
Target product profile for cell-based and gene-based therapies to achieve a cure for HIV
|
Lewin, Sharon R
|
|
|
12 |
2 |
p. e154-e162
|
article
|
| 14 |
Thank you to The Lancet HIV's statistical and peer reviewers in 2024
|
The Lancet HIV Editors,
|
|
|
12 |
2 |
p. e88-e91
|
article
|
Journal description